Sectors > > Celsion Corp

Celsion Corp(NASDAQ:CLSN)

Showing 9 related news items

[Breaking News] Celsion Corporation Announces Convertible Preferred Stock Financing and Amended License Agreement for Aggregate Gross Proceeds of up to $9 Million

01/13/2011 7:27 a.m.

,an oncology drug development company dedicated to the development and commercialization of innovative oncology drugs, today announced that it has entered into a definitive securities purchase agreement with... Full Story

[Breaking News] Celsion Announces New Board Member

12/08/2010 7:43 a.m.

, a biotechnology drug development company that is leveraging its heat sensitive liposomal technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, announces the appoin... Full Story

[Breaking News] Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer

08/24/2010 9:53 a.m.

,a leading oncology drug development company, today announced that the U.S. Food and Drug Administration (FDA) has designated the HEAT Study of its investigational drug, ThermoDox(R), in combination with rad... Full Story

[Breaking News] Celsion's Phase III ThermoDox(R) HEAT Study Recommended as Priority Clinical Trial for HCC

08/03/2010 10:02 a.m.

announced today that the consensus recommendations of the National Cancer Institute (NCI) Clinical Trials Planning Meeting (CTPM) for Hepatocellular Carcinoma have been released and published in the August 2... Full Story

[Breaking News] Celsion Corporation Announces Transfer of Stock Listing to the NASDAQ Capital Market

07/09/2010 5:27 p.m.

,a biotechnology drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, announced today that ... Full Story

[Breaking News] Celsion Announces ThermoDox(R) Abstract Accepted at the American Society for Radiation Oncology 2010 Annual Meeting

06/14/2010 10:29 a.m.

announced today that an abstract on the Phase I/II DIGNITY trial of ThermoDox(R) in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 52nd American Society for Radiation ... Full Story

[Breaking News] Celsion Corporation Announces ThermoDox(R) Abstract Accepted for Presentation at the American Society of Clinical Oncology 2010 Annual Meeting

05/07/2010 10:47 a.m.

today announced that an abstract about the Phase I/II trial of ThermoDox(R) in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 A... Full Story

[Breaking News] Celsion Announces Oral Presentation of Phase I ThermoDox(R) Data At 2010 IHPBA World Congress

05/07/2010 10:46 a.m.

today announced that Dr Thanjavur S Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox(R) dose escalation trial, gave an oral presentation at the Liver Tumors ... Full Story

[Breaking News] Celsion Reports First Quarter 2010 Financial Results and Provides Business Update

05/04/2010 8:49 a.m.

,a leading oncology drug development company, announced today financial results for the first quarter ended March 31, 2010 and addressed the progression of the clinical trials of ThermoDox(R), Celsion's heat... Full Story